The Mississippi Society of Oncology was formed in 1991 for the purpose ofpromoting the highest professional standards of oncology in Mississippi, to study, research and exchange information, experiences and ideas leading to improvement in oncology and promote educational opportunities.
In addition, the MOS is committed to support the search for more effective treatments of malignant diseases, work with other organizations and societies that have concerns with cancer care, and disseminate information regarding regulatory developments affecting members.
And finally the MOS acts as a resource for insurers regarding the standard of care in oncology and represents the practice of oncology and hematology in the State of Mississippi.
Economic Cost of Cancer in U.S. Tops $94B Annually According to a Study State-by-state variations in cancer deaths suggest that effective cancer prevention and treatment could yield economic benefits, according to a study published in JAMA Oncology. Click here for more.
Denial Rates and Days to Pay for Cancer Drugs: Commercial Health Plan Report Card
Office-administered oncology drugs given in the community setting face stiff reimbursement challenges when billing commercial plans; while Medicare has emerged as the gold standard for both predictable payment and timeliness. Click here for more.
COA Launches Major National Campaign to Stop PBM Abuses and Highlight Patient Horror Stories
COA recently launched a major national campaign to highlight the negative impact of pharmacy benefit managers (PBMs) on patients with cancer. The “PBM Abuses” campaign will ensure that PBM middlemen's abuse of patients with cancer is not lost in policy deliberations in Washington.
CMS' "Fail First" Step Therapy Policy Means Medicare Patients with Cancer Will Face More Dangerous Delays and Denials
Earlier this month, the Centers for Medicare & Medicaid Services (CMS) codified its decision to allow MA plans to use “fail first” step therapy for new starts of Part B drugs for cancer and other serious diseases. The Trump administration’s decision to finalize step therapy in MA plans means that Medicare patients with cancer will face nightmares of delays and denials while trying to access their physician-prescribed treatments